MarketCapTrends
VTGN
VistaGen Therapeutics Inc. (VTGN)
NASDAQ · Healthcare

VistaGen Therapeutics Inc. Shareholder Equity 2011–2025

VistaGen Therapeutics Inc. annual/quarterly shareholder equity history from 2011 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.

  • VistaGen Therapeutics Inc. shareholder equity for the quarter ending March 31, 2025 were 70.4M, a 38.41% decrease year-over-year.
  • VistaGen Therapeutics Inc. shareholder equity for 2025 were 70.4M, a 38.41% decrease from 2024.
  • VistaGen Therapeutics Inc. shareholder equity for 2024 were 114.3M, a 846.08% increase from 2023.
  • VistaGen Therapeutics Inc. shareholder equity for 2023 were 12.1M, a 81.33% decrease from 2022.
  • VistaGen Therapeutics Inc. shareholder equity for 2022 were 64.7M.
Shareholder Equity
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
VistaGen Therapeutics Inc. Annual Shareholder Equity (Millions of US $)
2025$70
2024$114
2023$12
2022$65
2021$92
2020$-6
2018$7
2017$1
2016$-3
2013$-13
2012$-6
2011$-33
VistaGen Therapeutics Inc. Quarterly Shareholder Equity (Millions of US $)
2025-03-31$70
2024-03-31$114
2023-03-31$12
2022-03-31$65
2021-03-31$92
2020-03-31$-6
2018-03-31$7
2017-03-31$1
2016-03-31$-3
2013-03-31$-13
2012-03-31$-6
2011-03-31$-33

VistaGen Therapeutics Inc. Shareholder Equity — FAQ

VistaGen Therapeutics Inc. (VTGN) shareholder equity over the last 12 years — annual and quarterly figures with year-over-year growth and charts.

Where can I see VTGN's shareholder equity history?

The chart and table above show VistaGen Therapeutics Inc.'s shareholder equity by year and by quarter, including the growth rate.